Kaijser G P, Underberg W J, Beijnen J H
Pharmaceutical Laboratory, Utrecht University, The Netherlands.
Pharm Weekbl Sci. 1990 Dec 14;12(6):228-35. doi: 10.1007/BF01967822.
Presuming that preparation of antineoplastic drugs without proper protection may lead to mutagenic urine (of which the effects are uncertain), one has to take great care when preparing these drugs. Apart from Norway no other country has national regulations issued by the government for handling cytostatic agents. Many organizations in various countries have made their own guidelines, which may be adapted to the situations in local hospitals. The following recommendations have been compiled after a review of the literature. They reflect a personal set of guidelines for preparation, administration and disposal of cytotoxic drugs. They are probably the minimum precautions that should be taken, and have not been approved by any committee or agency. Further precautions must first have their potential benefit weighed against probable inconvenience and additional costs.
假设在没有适当防护的情况下配制抗肿瘤药物可能会导致尿液发生诱变（其影响尚不确定），那么在配制这些药物时必须格外小心。除挪威外，没有其他国家由政府发布关于处理细胞毒性药物的国家法规。各国的许多组织都制定了自己的指南，这些指南可能会根据当地医院的情况进行调整。以下建议是在查阅文献后汇编而成的。它们反映了一套关于细胞毒性药物配制、给药和处置的个人指南。它们可能是应该采取的最低限度预防措施，并且尚未得到任何委员会或机构的批准。进一步的预防措施必须首先权衡其潜在益处与可能带来的不便和额外成本。
